Among patients with T2DM who do not achieve individualized HbA1c targets with oral agents, initiation of basal insulin is recommended as the first injectable therapy, a strategy well-established in clinical guidelines due to its efficacy, ease of use, and lower risk of hypoglycemia compared to more complex regimens [20, 46]. The gene discussed is INS; the disease is type 2 diabetes mellitus.